OXALIPLATIN IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH CERVICAL CANCER

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项I-II期研究的目的是确定局部复发或转移性宫颈癌患者的应答率、毒性和恢复情况。这项研究的基本原理是，接受化疗/放射治疗的转移性(骨盆外)疾病患者的存活率没有改善。顺铂一直是最活跃的药物，但在临床结果方面没有任何改善。顺铂/紫杉醇可提高缓解率，但不能提高存活率。研究人员现在将尝试奥沙利铂，它已被证明对一些顺铂耐药肿瘤有效。此外，奥沙利铂没有明显的肾脏毒性，在这个队列中肾脏受累的发生率很高。研究的终点是可测量和不可测量的疾病；完全应答、部分应答等；毒性和恢复。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The aim of this phase I-II study is to determine the response rates and toxicities and recovery for patients with locally recurrent or metastatic cervical cancer. The rationale of the study is that there has been no improvement in survival in patients with metastatic (outside the pelvis) disease with chemotherapy/radiotherapy. Cisplatin has been the most active agent but has shown no improvement in clinical outcome. Cisplatinum/paclitaxel improves the response rate but not survival. The investigators will now try oxaliplatin, which has been shown to be active in some cisplatinum-resistant tumors. Also, there is no significant renal toxicity with oxaliplatin, and there has been a high incidence of renal involvement in this cohort. Endpoints of the study are measurable and non-measurable disease; complete response, partial response, etc; toxicity and recovery.